EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study

Malia A Belnap, Katie Witkiewitz iD, Joseph P Schacht iD, Raymond F Anton iD, Arnie P Aldridge, Steven J Nieto iD, Lara A Ray iD

Alcohol, Clinical and Experimental Research · 2026-06 · 50 (6)

DOI: 10.1111/acer.70306 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Alcohol, Clinical and Experimental Research, online erschienen am 12.06.2026. Verfasst von Malia A Belnap und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Interdepartmental Program, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Alcoholism, Randomized Controlled Trials as Topic, Alcohol Deterrents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The U.S. Food and Drug Administration (FDA) recommends a minimum duration of 6 months for randomized controlled trials (RCTs) evaluating pharmacotherapies for alcohol use disorder (AUD). The relationship between trial length and treatment effects is not well understood. The current study conducted meta‐regression analyses of RCTs for AUD to examine the association between trial length and observed medication effect sizes in clinical trials.

Methods

This secondary data analysis utilized data from a systematic literature review that identified 139 pharmacotherapy RCTs for AUD conducted between 1985 and 2023. Meta‐regressions were conducted using the metafor package in R to examine whether shorter (< 12 weeks) or longer (> 12 weeks) trials differed in observed medication effect sizes for abstinence‐ and drinking‐based endpoints, relative to 12‐week trials, which represented the median trial duration. Publication bias was addressed using a weight‐function model.

Results

For abstinence‐based endpoints, neither shorter (< 12 weeks; β = 0.13, SE = 0.21, p = 0.54) nor longer (> 12 weeks; β = 0.11, SE = 0.11, p = 0.30) trials differed significantly from the 12‐week reference group in observed medication effect sizes. Similarly, for drinking‐based endpoints, neither shorter (< 12 weeks; β = −0.07, SE = 0.09, p = 0.39) nor longer (> 12 weeks; β = 0.06, SE = 0.05, p = 0.26) trials differed significantly from 12‐week trials in observed medication effect sizes. All results remained nonsignificant after adjusting for publication bias. In sensitivity analyses restricted to trials with statistically significant effect sizes, trials > 12 weeks showed smaller estimated treatment effects compared to trials ≤ 12 weeks.

Conclusions

Observed medication effect sizes did not differ significantly across trial lengths for abstinence and drinking‐based endpoints, except for analyses restricted to trials with significant effect sizes, where there was an advantage for trials that were 12 weeks or shorter. These findings inform efforts to optimize AUD RCT design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlcoholismRandomized Controlled Trials as TopicAlcohol DeterrentsHumansTime FactorsTreatment OutcomeRegression Analysis

Stichwörter der Autor:innen

alcohol use disorderclinical trial designmeta‐regressionpharmacotherapytreatment duration

Substanzen

Alcohol Deterrents

Autor:innen und Institutionen

  • Neuroscience Interdepartmental Program, University of California, Los Angeles, California, USA.
  • Department of Psychology, University of California, Los Angeles, California, USA.
  • Center on Alcohol, Substance Use, and Addictions (CASAA), University of New Mexico, Albuquerque, New Mexico, USA.
  • Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA.
  • Department of Psychiatry, University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA.
  • Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID-Profile: Katie Witkiewitz, Joseph P Schacht, Raymond F Anton, Steven J Nieto, Lara A Ray

Förderung

  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Belnap, M. A., Witkiewitz, K., Schacht, J. P., Anton, R. F., Aldridge, A. P., Nieto, S. J., & Ray, L. A. (2026). Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study. Alcohol, Clinical and Experimental Research, 50(6). https://doi.org/10.1111/acer.70306

Vancouver

Belnap MA, Witkiewitz K, Schacht JP, Anton RF, Aldridge AP, Nieto SJ, et al. Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study. Alcohol, Clinical and Experimental Research. 2026;50(6). doi:10.1111/acer.70306

BibTeX
@article{Belnap2026,
  author = {Belnap, Malia A and Witkiewitz, Katie and Schacht, Joseph P and Anton, Raymond F and Aldridge, Arnie P and Nieto, Steven J and Ray, Lara A},
  title = {Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study},
  journal = {Alcohol, Clinical and Experimental Research},
  year = {2026},
  volume = {50},
  number = {6},
  doi = {10.1111/acer.70306}
}
Kostenlos starten →